Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients with HCV-genotype 2/3 chronic hepatitis C documented by detectable plasma HCV RNA (\> 15 IU/mL) and positivity of anti-HCV antibodies~* Age ≥ 18 years~* Compensated liver disease (Child-Pugh Grade A clinical classification)~* Negative urine or blood pregnancy test (one of the both; for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug. Additionally, all fertile males and females must be using two forms of effective contraception during treatment and during the 7 months after treatment end. This includes using birth control pills (no interaction with investigational drugs), IUDs, condoms, diaphragms, or implants, being surgically sterilized, or being in a post-menopausal state. At least one contraception method must be of barrier method~* Ongoing treatment with 1.5 µg/kg Peg-Interferon alpha-2b (PegIntron®) and \> 10.6 mg/kg ribavirin (Rebetol®)~* No rapid virological response (HCV-RNA positive after week 4 of the ongoing therapy)~* Willingness to give written informed consent and willingness to participate to and to comply with the study protocol~Exclusion Criteria:~* Women with ongoing pregnancy or breast feeding~* Male partners of women who are pregnant~* Positive tests at screening for anti-HAV IgM Ab, HBsAg, anti-HBc IgM Ab, HBeAg, anti-HIV, HIV-RNA~* History or other evidence of a medical condition associated with chronic liver disease other than HCV associated (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin exposures)~* History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease~* Patients with liver cirrhosis with a lesion suspicious for hepatic malignancy on the screening~* Absolute neutrophil count (ANC) \<750 cells/mm3 at screening~* Platelet count \<50,000 cells/mm3 at screening~* Hb \<10 g/dl at screening~* Dose modification of Peg-Interferon alpha-2b (PegIntron®) or ribavirin (Rebetol®) during the first 4 weeks of the ongoing therapy~* Interferon alpha or ribavirin therapy at any time point before the actual ongoing treatment~* Less than 80% adherence to treatment of the ongoing treatment until randomization (week 20-22 of ongoing treatment)~* Serum creatinine level \>1.5 times the upper limit of normal at screening~* History of severe psychiatric disease, especially depression (ICD 10 codes F30-F33). Severe psychiatric disease is defined as treatment with an antidepressant medication or a major tranquilizer at therapeutic doses for major depression or psychosis, respectively, for at least 3 months at any previous time. Patients are excluded if any history of suicidal attempts is evident. If hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease are documented, psychiatric consultation is mandatory. Patients with a mild or moderate psychiatric disease (ICD 10 codes F32.0, F32.1, F33.0, F33.1) are only allowed to be included into the trial if a regular monitoring by a psychiatrist is performed during the trial~* History of a severe seizure disorder or current anticonvulsant use~* History of immunologically mediated disease (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis)~* History or any other evidence of autoimmune diseases~* History or other evidence of chronic pulmonary disease associated with functional limitation~* History of significant cardiac disease that could be worsened by acute anemia (e.g. NYHA Functional Class III or IV, myocardial infarction within 6 months prior to treatment with Peg-Interferon/ribavirin therapy, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina)~* Evidence of thyroid disease that is poorly controlled on prescribed medications~* Evidence of severe retinopathy (e.g. CMV retinitis, macular degeneration)~* History of major organ transplantation with an existing functional graft~* History or other evidence of severe illness, malignancy or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study~* History of any systemic anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) 6 months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study~* Patients with evidence for tuberculosis~* Drug abuse within 6 months prior to the first dose of study drug and excessive alcohol consumption. Patients on methadone/polamidone/buprenorphine programs are not excluded~* Any investigational drug and/or participation in another clinical study prior 6 months to the actual ongoing antiviral treatment~* Limited contractual capability

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): PegIntron® 1.5 µg/kg once weekly (QW) subcutaneous (sc) plus Rebetol® 800-1400 mg per os divided in 2 daily doses for additional 24 weeks beyond standard treatment with 24 weeks follow-up
- B (Type: ACTIVE_COMPARATOR): PegIntron® 1.5 µg/kg QW sc plus Rebetol® 800-1400 mg per os divided in 2 daily doses for additional 12 weeks beyond standard treatment with 24 weeks follow-up

Based on this trial design, predict the completion outcome and termination type (if applicable).